Market access webinar

How to demonstrate the value of vaccines in line with global NITAG and HTA requirements

Fill in your details to watch this webinar

We respect your privacy. Cookie policy.

Since 2020, vaccine development and evidence-based evaluation by national immunization technical advisory groups (NITAGs) and health technology assessment (HTA) agencies have become important line items in pharmaceutical investment and strategic planning. 

Now more than ever, HEOR and market access teams need to ensure they have a deep understanding of vaccine evaluation requirements to plan for success. 

During this webinar, you will gain an analysis of the global requirements of NITAGs and HTA agencies for vaccine evaluation, and learn how you can provide your team with the materials they need to demonstrate value. 

Learning aims

  • Understand which stakeholders are involved in vaccine evaluation, and global NITAG and HTA requirements. 
  • Appreciate the differences in vaccine modeling requirements among markets. 
  • Explore how to develop global value dossiers that meet the needs of NITAGs and HTA agencies. 



Claire has more than 10 years’ experience in market access, with a particular interest in defining evidence generation strategies and developing value demonstration materials, including payer marketing materials, product value dossiers, HTA submissions, and HEOR publications. 

Claire has provided strategic and editorial support across several therapeutic areas, including oncology, arthropathies, infection, diabetes, and neuroscience. As a member of the PRMA Navigator® digital application team, Claire leads delivery of PRMA Navigator® projects. 



Marie has more than 10 years’ experience in the pharmaceutical industry working across multiple therapy areas and indications including dermatology (eczema, psoriasis), infectious diseases (HIV, malaria), rheumatoid arthritis, and oncology. 

Marie has worked on projects that have involved development of viral vector vaccines, pediatric antimalarials, and novel parenteral delivery systems for use in HIV. 


With more than 10 years’ experience in market access consultancy and research, Vanya has a broad understanding of pricing and reimbursement processes across different markets. She has been involved in a wide variety of projects including HTA reviews and development of eligible patient population models and global value dossiers. 

Vanya has been heavily involved in the development of the PRMA Navigator® digital application, researching and adapting HTA and other payer submission templates, and using the application to develop HTA submissions across a range of therapy areas. 

Duration: 30 minutes.

Ideal viewing:

This update is essential viewing for all those in global and regional market access and HEOR roles. It is of special interest to those who want to improve global value dossier development to meet local payer needs. 

Broadcast: 2021

How to demonstrate the value of vaccines in line with global NITAG and HTA requirements